title: PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.
abstract: In this review, we examine alirocumab (Praluent(®)), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.
authors.affiliation: MedStar Franklin Square Medical Center, Department of Medicine, Baltimore, MD, USA.
authors.forename: Chanukya
authors.initials: C
authors.lastname: Dahagam
authors.affiliation: MedStar Franklin Square Medical Center, Department of Medicine, Baltimore, MD, USA.
authors.forename: Aditya
authors.initials: A
authors.lastname: Goud
authors.affiliation: MedStar Franklin Square Medical Center, Department of Medicine, Baltimore, MD, USA.
authors.forename: Abdelhai
authors.initials: A
authors.lastname: Abdelqader
authors.affiliation: MedStar Good Samaritan/Union Memorial Hospital, Department of Medicine, Baltimore, MD, USA.
authors.forename: Aditya
authors.initials: A
authors.lastname: Hendrani
authors.affiliation: Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Feinstein
authors.affiliation: Cardiovascular Division, Brigham & Womens Hospital, Boston, MA, USA.
authors.forename: Arman
authors.initials: A
authors.lastname: Qamar
authors.affiliation: Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Parag H
authors.initials: PH
authors.lastname: Joshi
authors.affiliation: Cardiovascular Division, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Kristopher J
authors.initials: KJ
authors.lastname: Swiger
authors.affiliation: Pediatric Cardiology, Johns Hopkins Hospital, Baltimore, MD, USA.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Byrne
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Renato
authors.initials: R
authors.lastname: Quispe
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Jones
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Roger S
authors.initials: RS
authors.lastname: Blumenthal
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Seth S
authors.initials: SS
authors.lastname: Martin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL / Q000097:blood*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; C571059:alirocumab
keywords: LDL; PCSK9 inhibitors; alirocumab; evolocumab; monoclonal antibodies; statin intolerance